This article is based on a poster originally authored by Enhanc3D Genomics, which was presented at ELRIG Drug Discovery 2024 in affiliation with Enhanc3D Genomics.
This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment.
The third dimension of DNA
Image Credit: Enhanc3D Genomics
- Only 2 % of your DNA codes for proteins
- 95 % of disease variance remains hidden in the non-coding DNA
- DNA folding results in promoter-enhancer interactions
- Interactions between enhancers and promoters are critical to cell regulation
The power of GenLink discovery
This proprietary 3D genomics platform provides a unique combination of unbiased genome-wide screening across multiple disease areas and cell backgrounds, making it a true discovery tool.
Image Credit: Enhanc3D Genomics
Products
- Dive into the next dimension of discovery
- Harness the platform for enhanced genomic understanding of your disease/cell of interest
- Three powerful solutions, one integrated platform
Image Credit: Enhanc3D Genomics
Discovery pipeline and big data
- Enhanced Genomics has a robust pipeline of discovery across multiple disease indications.
- Further investment and partnership will support the further development of the platform and the assets it generates.
- The long-term vision is to generate novel disease insights and solve bottlenecks in genomics approaches to therapeutics and cell engineering.
Image Credit: Enhanc3D Genomics
About Enhanc3D Genomics
ENHANC3D GENOMICS creates new applications to improve human healthcare. Our disruptive technology profiles 3D genome folding at high resolution for all genes and their enhancers simultaneously and thus links gene enhancers and non-coding genetic variants to their target genes to unlock their potential for therapeutic discovery.
Enhanc3D Genomics is a spinout company from Babraham Institute (Cambridge, UK), founded by academic scientists who are leaders in the fields of regulatory genomics and chromosomal architecture. Enhanc3D Genomics is a privately held company headquartered in Cambridge, UK.
About ELRIG (UK) Ltd.
The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. The foundation of the organization is based on the use and application of automation, robotics and instrumentation in life science laboratories, but over time, we have evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionize drug discovery.
Comprised of a global community of over 12,000 life science professionals, participating in our events, whether it be at one of our scientific conferences or one of our networking meetings, will enable any of our community to exchange information, within disciplines and across academic and biopharmaceutical organizations, on an open access basis, as all our events are free-of-charge to attend!
Our values
Our values are to always ensure the highest quality of content and that content will be made readily accessible to all, and that we will always be an inclusive organization, serving a diverse scientific network. In addition, ELRIG will always be a volunteer led organization, run by and for the life sciences community, on a not-for-profit basis.
Our purpose
ELRIG is a company whose purpose is to bring the life science and drug discovery communities together to learn, share, connect, innovate and collaborate, on an open access basis. We achieve this through the provision of world class conferences, networking events, webinars and digital content.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.